What the trial was testing
The NOVA1 enrolled 359 patients with schizophrenia. The study was sponsored by LB Pharmaceuticals Inc. and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was initial testing (phase 2). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
LB-102 at 50 mg and 75 mg reduced schizophrenia symptoms significantly more than placebo over 4 weeks.
JAMA psychiatry · 2026 · NCT06179108
These findings — that lB-102 50 mg and 75 mg reduced symptom scores approximately 50% more than placebo — were published in the JAMA psychiatry and represent the headline result of the study.
Researchers tracked outcomes across 359 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with schizophrenia, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
This early-stage trial shows promise for a new antipsychotic option in acute schizophrenia. The medication improved symptoms faster than placebo, though side effects were common. More testing is needed before this treatment becomes available—ask your doctor about current trials or approved antipsychotics for acute symptoms.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open schizophrenia trials
Uppsala Psychosis Cohort
A multimodal longitudinal study in early stage psychosis patients and individuals at high risk for psychosis. Healthy controls are included for baseline comparisons. The aim is to investigate disease mechanisms of psychotic disorders, specifically focusing on the synaptic pruning hypothesis.
Early Identification of Patients Presenting a First Psychotic Episode, Non Answering to First Line Support Strategies
Researchers propose in this project to evaluate predictive factors of non response. It is defined by the lack of symptomatic remission at month 3, for patients presenting a first episode of psychosis. It will be performed on objective markers taken from imagery techniques. The link between evolution of these markers and clinical measures will be studied.